Brokerages Expect Arrowhead Pharmaceuticals Inc (ARWR) to Announce -$0.15 Earnings Per Share

Wall Street analysts predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Arrowhead Pharmaceuticals’ earnings, with estimates ranging from ($0.22) to ($0.07). Arrowhead Pharmaceuticals posted earnings per share of ($0.14) in the same quarter last year, which indicates a negative year over year growth rate of 7.1%. The company is scheduled to issue its next earnings report on Tuesday, December 11th.

According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full-year earnings of ($0.65) per share for the current fiscal year, with EPS estimates ranging from ($0.76) to ($0.56). For the next fiscal year, analysts forecast that the business will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.88) to $0.30. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $0.62 million. Arrowhead Pharmaceuticals had a negative net margin of 400.13% and a negative return on equity of 59.39%.

A number of analysts recently issued reports on the stock. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Cantor Fitzgerald increased their target price on shares of Arrowhead Pharmaceuticals from $18.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday. Piper Jaffray Companies reissued an “overweight” rating and set a $25.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday. Jefferies Financial Group increased their target price on shares of Arrowhead Pharmaceuticals to $24.00 and gave the stock a “buy” rating in a research report on Friday, September 14th. Finally, Chardan Capital upped their price target on Arrowhead Pharmaceuticals from $17.50 to $24.50 and gave the stock a “buy” rating in a report on Thursday, September 6th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $21.36.

ARWR traded down $0.99 on Wednesday, reaching $13.75. 5,628,001 shares of the company’s stock were exchanged, compared to its average volume of 2,057,796. The company has a market cap of $1.69 billion, a PE ratio of -28.53 and a beta of 1.74. Arrowhead Pharmaceuticals has a twelve month low of $3.01 and a twelve month high of $22.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.69 and a current ratio of 8.69.

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 45,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $19.34, for a total value of $870,300.00. Following the completion of the transaction, the chief financial officer now owns 335,815 shares in the company, valued at approximately $6,494,662.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $14.45, for a total value of $1,445,000.00. Following the completion of the transaction, the chief executive officer now owns 1,868,789 shares of the company’s stock, valued at approximately $27,004,001.05. The disclosure for this sale can be found here. In the last 90 days, insiders sold 309,834 shares of company stock valued at $4,697,151. 4.60% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $100,000. Great West Life Assurance Co. Can purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $106,000. Macquarie Group Ltd. purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $151,000. Amalgamated Bank purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $181,000. Finally, Legal & General Group Plc purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $188,000. Institutional investors own 58.77% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Featured Article: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply